Objective: To investigate the pathogenesis of coronary slow flow (CSF), C-reactive protein (CRP) levels as indicator of inflammation and procoagulant activity were studied in patients with CSF.
Methods: Fifty-one patients (22 female, mean age; 53+/-10 years) who were admitted to our clinic with chest pain and had the diagnosis of CSF established by TIMI frame count method and coronary angiography, and 44 healthy subjects (18 female, mean age; 546 years) with normal coronary flow (NCF) were included in the study. Subjects with any infectious and systemic immune disease were excluded from the study. The CRP levels were measured from venous blood samples during admission, at 24th hour and after 3 months in all subjects. Additionally; fibrinogen, plasminogen, plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) levels were measured to determine the procoagulant activity.
Results: There was no significant difference between CRP levels of patients with CSF and healthy subjects during admission (7.26+/-4.2 ng/dl vs. 6.43+/-2.8 ng/dl, p>0.05), at 24th hour (7.84+/-1.3 ng/dl vs. 6.32+/-2.5 ng/dl, p>0.05) and after 3 months (6.37+/-2.4 ng/dl vs. 6.18+/-3.3 ng/dl, p>0.05). There were no differences between levels of CRP when compared according to the TIMI frame count, number of vessels with CSF and artery in which CSF was dominant. Additionally; procoagulant activity assessed by fibrinogen, plasminogen, PAI-1, t-PA and vWF levels was similar in both groups.
Conclusion: Our findings on normal levels of CRP and procoagulant activity, and lack of relation with TIMI frame count made us to think that inflammatory and procoagulant activity did not play a role in the pathogenesis of CSF.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism.
Res Pract Thromb Haemost
January 2025
Thrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
Background: A high level of plasma coagulation factor (F)VIII is an established and likely causal risk factor for venous thromboembolism (VTE). Procoagulant phospholipids (PPLs) facilitate FVIII activity in coagulation.
Objectives: To assess the association between plasma levels of FVIII and risk of future VTE according to PPL clotting time (PPL), an inverse surrogate measure of plasma PPL activity.
Mice with Reduced PAR4 Reactivity show Decreased Venous Thrombosis and Platelet Procoagulant Activity.
J Thromb Haemost
January 2025
Case Western Reserve University, School of Medicine, Department of Pharmacology, Cleveland, OH United States. Electronic address:
Background: Hypercoagulation and thrombin generation are major risk factors for venous thrombosis. Sustained thrombin signaling through PAR4 promotes platelet activation, phosphatidylserine exposure, and subsequent thrombin generation. A single-nucleotide polymorphism in PAR4 (rs2227376) changes proline to leucine extracellular loop 3 (P310L), which decreases PAR4 reactivity and is associated with a lower risk for venous thromboembolism (VTE) in a GWAS meta-analysis.
View Article and Find Full Text PDFChemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis.
Thromb Res
December 2024
Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland; Trinity St. James's Cancer Institute, Dublin, Ireland. Electronic address:
Background: Tumour type, treatment and patient related factors contribute to cancer associated venous thromboembolism (VTE), however, the role of each factor and the mechanisms involved are not understood.
Aim: To assess the role of the tumour, and of chemotherapy, in mediating the procoagulant response associated with VTE in gynaecological cancer patients.
Methods: Gynaecological cancer patients who developed VTE during follow-up (n = 59) (VTE+) were matched with treatment naïve(treatment (-)(VTE-)(n = 120) and chemotherapy treated patients(treatment (+)(VTE-) (n = 57)).
Understanding the effects of Bothrops erythromelas and Bothrops leucurus venoms on human blood coagulation.
Toxicon
January 2025
Laboratório de Fisiopatologia, Instituto Butantan, São Paulo, Brazil; Programa de Pós-Graduação Interunidades em Biotecnologia, São Paulo, Brazil; Laboratório de Fisiopatologia, Instituto Butantan, São Paulo, Brazil. Electronic address:
Coagulation disorders are a primary symptom of envenomation caused by snakes belonging to the genus Bothrops. In the Northeast region of Brazil, the species Bothrops erythromelas and Bothrops leucurus are the main responsible for snakebite accidents. Due to the specific action of Bothrops venoms on several components of the coagulation cascade, the objective of this work was to characterize the coagulotoxic profile of B.
View Article and Find Full Text PDFMissing the mark(ers): circulating endothelial cells and endothelial-derived extracellular vesicles are elevated in sickle cell disease plasma.
Front Immunol
January 2025
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, United States.
Sickle cell disease (SCD) is a devastating hemolytic disease, marked by recurring bouts of painful vaso-occlusion, leading to tissue damage from ischemia/reperfusion pathophysiology. Central to this process are oxidative stress, endothelial cell activation, inflammation, and vascular dysfunction. The endothelium exhibits a pro-inflammatory, pro-coagulant, and enhanced permeability phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!